1. Home
  2. BXC vs PHAT Comparison

BXC vs PHAT Comparison

Compare BXC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluelinx Holdings Inc.

BXC

Bluelinx Holdings Inc.

N/A

Current Price

$73.79

Market Cap

706.5M

ML Signal

N/A

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

N/A

Current Price

$7.12

Market Cap

590.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BXC
PHAT
Founded
2004
2018
Country
United States
United States
Employees
1700
371
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
706.5M
590.6M
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
BXC
PHAT
Price
$73.79
$7.12
Analyst Decision
Buy
Buy
Analyst Count
4
12
Target Price
★ $88.33
$20.45
AVG Volume (30 Days)
108.0K
★ 1.1M
Earning Date
11-03-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 42.72
EPS
★ 0.62
N/A
Revenue
N/A
★ $175,110,000.00
Revenue This Year
$5.56
$80.50
Revenue Next Year
$4.54
$56.64
P/E Ratio
$120.85
★ N/A
Revenue Growth
N/A
★ 216.93
52 Week Low
$44.78
$6.91
52 Week High
$93.80
$18.31

Technical Indicators

Market Signals
Indicator
BXC
PHAT
Relative Strength Index (RSI) 41.00 37.55
Support Level $47.84 $6.91
Resistance Level $81.73 $9.74
Average True Range (ATR) 3.89 0.39
MACD -0.89 -0.00
Stochastic Oscillator 2.14 23.18

Price Performance

Historical Comparison
BXC
PHAT

About BXC Bluelinx Holdings Inc.

BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh, and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: